Kirschner Medical Corp. of Timonium says it will continue most of its exports of orthopedic products despite the removal of a Food and Drug Administration certificate of export this week.
The financial impact of the FDA's action on the company will be "negligible," Kirschner Chief Executive C. Scott Harrison said yesterday.
The certificate assures foreign countries there is no problem with the manufacturing process, the FDA said, but is not required.
After consulting with legal counsel, Mr. Harrison said, the company will continue shipping to more than 30 companies. Only hip, knee and shoulder replacements are affected. The FDA has not said what prompted its action.
Kirschner was expected to finish its sale to Henley International Inc. of Houston today. Henley said it still hopes to complete the negotiations despite the loss of the certificate.